New Pharmatech CEO expects larger external sales – but this won't weaken relationship with Novo Nordisk

Ulla Grove Krogsgaard Thomsen is the new CEO for Novo Nordisk Pharmatech, and according to the CEO, external sales will take up more space in the future. At the same time, she establishes that this will not weaken the firm's relationship with parent company Novo Nordisk.

New CEO for Novo Nordisk Pharmatech Ulla Grove Krogsgaard Thomsen. | Photo: Novo Nordisk Pharmatech / PR

From April 1, Ulla Grove Krogsgaard Thomsen will lead Novo Nordisk Pharmatech, and the future CEO expects sales for the company's external clients will take up an even larger portion during her management in future years, she tells MedWatch.

"Yes, I definitely think that external sales will be taking up even more space. But naturally, we also have our resins foundation, where Novo Nordisk sales take up a large position," Grove Krogsgaard Thomsen says and adds:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs